- Osiris Therapeutics (OSIR) leaps 57% after saying its stem-cell based biosurgery product Grafix closed three times as many wounds as conventional treatment in a study of patients with a diabetic foot ulcer.
- In the trial, 62% of patients receiving Grafix enjoyed complete wound closure vs only 21% who received standard care.
- Grafix also closed wounds faster and needed fewer treatments.
- Around a quarter of diabetics develop diabetic foot ulcers. (PR)
Osiris shares jump following study results for Grafix
Aug 13 2013, 09:35 ET